MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING
The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
1 .- 24 . (canceled)
25 . A method for treatment or prophylaxis of a herpes viral infection in a patient in need thereof comprising administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound, in an amount effective to counteract molecular conversion of said compound occurring in vivo, and thereby providing an anti-virally effective amount of said compound to said patient.
26 . A method according to claim 25 , wherein said amount is greater than 200 mg per day.
27 . A method according to claim 26 , wherein the amount administered is up to 6400 mg per day.
28 . A method according to claim 25 , wherein said herpes viral infection is cytomegalovirus.
29 . A method according to claim 28 , wherein said patient is a stem cell transplant recipient, a liver transplant recipient, or kidney transplant recipient.
30 . A method according to claim 25 , wherein said compound is administered to said patient under fasted conditions.
31 . The method of claim 25 , wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient or carrier medium.
32 . The method of claim 31 , wherein said composition is an immediate release formulation, a delayed release formulation, a controlled release formulation or an intravenous formulation.
33 . The method of claim 25 , wherein said compound is administered in combination with at least one of an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir, an antibiotic having activity against a microorganism that mediates isomerization of maribavir and an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of said compound.
34 . A method of increasing the bioavailability of maribavir to a patient receiving maribavir therapy comprising administering to said patient an oral dose comprising about 200 mg to 800 mg of maribavir under fasted conditions, whereby said administration results in an increase of the maximum plasma concentration and the extent of absorption of maribavir relative to the plasma concentration and the extent of absorption for the corresponding administration of maribavir under fed conditions.
35 . A method of informing a patient receiving maribavir therapy that dosing of maribavir under fasted conditions results in an increase of the maximum plasma concentration as compared to the administration of maribavir under fed conditions, comprising providing to said patient a container of maribavir doses, said container being associated with prescription information that advises the patient that administration of a maribavir dose under fasted conditions results in said increase.
36 . A method of making one or more maribavir isomers comprising the step of administering maribavir to a mammal, wherein said administration results in the in vivo isomerization of maribavir to one or more maribavir isomers.
37 . The method according to claim 36 , wherein the said mammal is human that has a herpes virus infection.